Oct 2 () - Chinese biotech company Abogen said on Friday it ‌signed a licensing deal worth ‌about $7.8 billion with Swiss drug maker ​Novartis to advance RNA-based therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results